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containing Na125l. To this mixture was added chlora
mine-T. Then sodium meta bisul?te was added to stop
the reaction.
U.S. Pat. No. 4,436,718 to Smith discloses an iodinat

NON-DESTRUCTIVE METHOD FOR
RADIOLABELLING BIOMOLECULES BY

HALOGENATION

ing reagent. This patent discloses that N-chloro~4
methylbenzenesulfonamide or chloramine-T has long

TECHNICAL FIELD
The present invention relates to a non-destructive

been used as the oxidant to mediate iodination reactions.
The disclosure states that the use of chloramine-T has
its drawbacks. The oxidant of Smith comprises a water

method for radiolabelling biomolecules by halogena

tion. The method for halogenating or iodinating chemi
cally sensitive substrates of the invention employs a 10 insoluble bead having covalently attached to its surface
molecules a chloramine group, with a size and shape of
secondary amine to reduce the oxidation potential of
the bead being compatible with easy physical separation
chloramine-T (sodium-p-toluene sulfo-chloramine or
of the oxidant from a solution of the biological speci
CAT) or other chlorinating agent. The present inven
tion has been found to produce more complete haloge
men. In the invention of Smith, chlorosulfonic acid,
nation or iodination with less side reaction than the 5 aqueous ammonia, and sodium hypochlorite yield the
traditional methods in which CAT is bonded to poly
most preferred N-chlorobenzene sulfonamide function
mer beads. The method may be commercialized in kit
ality on the beads.
form.
U.S. Pat. No. 4,450,149 to Kabalka et al. discloses a

radiohalogenation method. In the method of Kabalka,
the general procedure for iodination involved adding

BACKGROUND ART
Frequently, it is desirable to radiolabel bioactive mol

methanol and organoborane. Iodine-mono-chloride is

ecules with radioactive iodine or other halogens such as

then added. Sodium thiosulfate is then added to the
mixture and the layers are dried over magnesium sul?te.

bromine. Most commonly, radioactive iodine is sup
plied in the form of KI* (wherein * represents a radioi

Benzoyl chloride was added to 4-penten-l-ol in pyridine
sotope of the halogen of interest, e.g., I125 or I131), and 25 and stirred overnight at room temperature. Sequen
the labeling procedure involves reaction of KI* with
tially, diluted HCl was added and the mixture was satu
chloramine-T (CAT) to release I;* followed by addi
rated with aqueous Na2CO3 and water.

tion of the substrate which then takes up the 12* to form
U.S. Pat. No. 4,528,134 to Stentz et al. discloses a
a radioiodinated product.
method
of iodinating insulin using chloramine-T. U.S.
A major drawback to this procedure occurs when the 30
Pat. No. 4,591,552 to Neurath discloses the detection of
substrate (compound to be labeled) is sensitive to oxida
hepatitis B surface antigen with labelled synthetic pep
tion or chlorination. Poor yields of 'the desired radi
tide.
This patent discloses that if a peptide contains
ohalogenated or radioiodinated product and possibly

tyrosine it can be labelled by contacting the peptide

complete decomposition of the substrate may occur
through oxidation or chlorination, if residual CAT is
left in the solution when the substrate is added.

with sodium I125 in a buffer and then oxidizing it in the
presence of chloramine-T. Neurath discloses that the
peptide can be labelled with or without a solid support

The IODOBEADS ® system (Pearce Chemical
Company) attempts to avoid the problem of substrate
decomposition by bonding the CAT onto polymer

such as polystyrene beads. U.S. Pat. No. 4,775,638 to

beads. A KI* solution is added to the beads and shaken 40
to release free 1*;. A solution of the substrate is then

Haisma discloses a single vial technique for radiolabell
ing protein. Haisma discloses use of coupling agents
such as iodogen (1,3,4,6-tetrachloro-3,6-diphenyl

added and shaken until the brown color disappears,

glycuril), chloramine-T, lactoperoxidase and iodine

then the beads are immediately ?ltered off to remove

monochloride. Iodination is conducted on an ion ex

change resin.

any residual CAT. The radioiodinated product is sepa

rated from the solution by preparative HPLC.
This system is only partially successful because CAT
is released from the beads very rapidly. With sensitive

45

U.S. Pat. No. 4,874,601 to Flanagan discloses a radi~

olabelling kit. The radiolabelling kit of Flanagan in
cludes oxidizing agents such the sodium salt of N
chloro-p-toluenesolufonamide or chloramine-T, iodo

substrates, if the manipulations are not carried out very

gen, or iodobeads (chloramine-T bonded to polystyrene
quickly, signi?cant amounts of CAT will appear in the
solution and decompose the substrate. In many cases, 50 beads). Flanagan does not disclose or suggest the use of
piperidine or N-chloro-piperidine in a method of radioi
the yields are very poor even though the procedure is
odination.
carried out as quickly as possible. Finally, preparation
U.S. Pat. No. 4,966,999 to Coughlin et al. discloses
of the polymer beads is relatively expensive.
radiohalogenated compounds for site speci?c labelling.
Methods are known for radioiodinating molecules
The process of Coughlin et al. includes an oxidant such
using chloramine-T (sodium-p-toluenesulfochlora
as chloramine-T, iodobeads or iodogen. Coughlin does
mine).
not disclose or suggest the use of piperidine or N
U.S. Pat. No. 3,867,518 to Coffey et al. describes a
chloro-piperidine in a method of radioiodination.
radioimmunoassay for insulin and further describes a
U.S. Pat. No. 4,994,258 to Burns et al. discloses novel
method for the preparation of radioiodinated insulin

using chloramine-T (sodium-p-toluenesulfochloramine)
and a phosphate buffer. Coffey et al. does not disclose
or suggest the use of piperidine or N-chloro-piperidine
in a method of radioiodination.
U.S. Pat. No. 4,196,185 to Focella discloses an immu~

60

radiolabelled antagonists for pancreatic imaging. The
radiolabelling process takes place in a sodium hydrox
ide solution of Na125I in the presence of cupric sulfate
and ammonium sulfate.
U.S. Pat. No. 5,084,266 to McKenzie et al. discloses a

noassay for phencyclidine. To prepare radioiodinated 65 method for tumor imaging utilizing a labelled tumor
speci?c antibody and a non-tumor reactive antibody.
N-(4-hydroxy-2-phenelthyl)-4-[l-piperidinyl)cy
McKenzie et al. found that the chloramine-T method
clohexyl] benzene acid sulfate, the compound was
placed in ethyl acetate and water was added to a vial
for radiolabelling resulted in a greater loss of immuno

3
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reactivity than either the iodobead or enzymobead
method. The enzymobead method was the method of
choice for labelling in the method of McKenzie et al.
US. Pat. No. 5,171,666 to Gutowski et al. discloses

4

strate-iodide-CAT-DMA mixture (Example 2a) on the

production of desired and side products for Gly-Try.
FIG. 3 shows the in?uence of time of preincubation
of the CAT-DMA mixture before the introduction into
the substrate iodine mixture on the production of the

the labelling of immunoglobulins using chloramine-T.

desired product for Gly-Tyr.
The publication of Markussen, J. et al., Insulin:
Chem, Struc. Funct. Insulin Relat. H0rm., Proc. Inzt,
FIG. 4 shows the in?uence of the DMA/CAT ratio
on the production of the desired product for Gly-Tyr.
Insulin Symp. (1980) pp. 16l—l68 is entitled “The Appli
FIG. 5 shows the iodination of Gly-Tyr by three
cation of HPLC to the Analysis of Radioiodinated
Tracers of Glucagon and Insulin”. This publication 0 methods employing Iodobeads ®.
FIG. 6 shows a comparison of Example 2a
discloses the use of chloramine T and lactoperoxidase in
the radioiodination of glucagon.

(CAT+DMA
solution)
with
Example
(Iodobeads ®+DMA) for iodination of Gly-Tyr.

The publication of Boothe, Thomas E. et al., J. La

belled Compd. Radiopharm, Vol. 23, (1986) pp.

4

DISCLOSURE OF THE INVENTION
The present invention provides a method of nonde

479-485, entitled “The Preparation of No-carrier

Added 4-[131I] iodoantipyrine using chloramine-T. The

structively radiolabelling a biomolecule substrate by

publication discloses the use of chloramine-T and iodo
gen to iodinate antipyrine for use as a tracer in studying

halogenation, comprising the steps of:

cerebral blood flow.

(a) reacting a secondary amine with a chlorinating
agent to produce an N-chloro secondary amine,
(b) reacting said N-chloro secondary amine with a

Dickinson, Kenneth E., et al., M01. PharmacoL, Vol.
26, No. 2, (1984) pp. l87—l95. “Photoaf?nity Crosslink
ing of a Radioiodinated Probe 125I-A55453, into Alpha

salt of a radiolabelled halogen to produce a radi

olabelled halogenating agent,

l-Adrenergic Receptors” discloses the radioiodina

(0) reacting a solution of said biomolecule substrate

tion of an alphal-adrenergic receptor probe. The

method of radioiodination includes the use of chlora 25 with said radiolabelled halogenating agent, and
(d) recovering a radiohalogenated biomolecule from
mine-T and Na125I.

the reaction of step (c).

Youfeng, He, et al., J. Labelled Compd. Radiopharm,
Vol. 19, (1982) pp. 807-819, “A Comparative Study of
Radioiodination of Simple Aromatic Compounds via

The invention also provides a method of producing a

radiolabelled halogenating agent for non-destructively
radiolabelling a substrate by halogenation, comprising

N-Halo-Succinimides and chloramine-T in Trifluoro

the steps of:
(a) reacting a secondary amine with a chlorinating
agent to produce an N-chloro secondary amine, and
(b) reacting said N-chloro secondary amine with the

acetic Anhydride (TFAA)”. This paper reports the

comparative results of radioiodination performed using

N-chlorotetratluorosuccinimide, N-chlorosuccinimide,
N-bromosuccinimide, and chloramine-T (CAT) as oxi
dizing agents with TFAA as an aprotic solvent. The
study concluded that CAT is a superior oxidizing agent
for the iodination of simple benzenes which are water

salt of a radiolabelled halogen to produce a radi

olabelled halogenating agent.
Additionally the invention provides a method of non

destructively radiolabelling a biomolecule substrate by

insoluble but which are soluble in TFAA.

radioiodination, comprising the steps of:
(a) mixing dry chloramine-T powder or chloramine

Nakamura, Masahiro, et al., Radioisoptopes, Vol. 40,
No. 3, (1991) pp. 112-117, “Preparation and Evaluation

T bonded to polymer beads, with a solution of a second~
ary amine to reduce the oxidation potential of chlora
mine-T, to form a mixture,

of Radio Labelled Recombinant Human Interleukin-2

by Improved Chloramine-T Method”. This publication

discloses the use of a very small quantity of chloramine
(b) shaking said mixture until all the chloramine-T
T to activate iodine (21 fold excess to iodine in molar 45 powder has dissolved,
ratio). This method of iododination is useful for iodin
(0) adding a solution of KI* or NaI* to said mixture,

ation of unstable peptides and proteins.
Baindur, Nandkishore, eta1., J. Med. Chem, Vol. 31,
No. 11, (1988) pp. 2069-2071, “Discloses a Photoaf
?nity Label for the D-1 Dopamine Receptor”. Radioi
odination methodology used by Baidur includes the use

wherein 1* represents a radioisotope of iodine,
(d) shaking said mixture of step (c) for a time suffi
cient to release 12* in solution,
50
(e) adding a solution of said biomolecule substrate to

said mixture,

of a modi?ed NaI-Chloramine-T procedure. None of
(f) shaking the resulting mixture of step (e) until the
the above patents or publications disclose or suggest the
brown color disappears, and
use of piperidine or N-chloro-piperidine in a method of
(g) recovering the radioiodinated biomolecule.
radioiodination.
55
Advantageously, the invention provides a kit for

The method of radiohalogenation of the present in

vention overcomes the de?ciencies of prior art methods
and provides an inexpensive method for radi
ohalogenating biomolecules which is non-destructive to
the biomolecule.
60

mine (DMA)—Example 2.
FIG. 2 shows the influence of incubation of the sub
strate-iodide-CAT (Example la) mixture or the sub

(a) a vial comprising a chlorinating agent, and
(b) a vial comprising a solution of a secondary amine,
(c) instructions for use.

The kit, preferably, further comprises a vial compris

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a comparison of two methods of iodin
ation of a Glysine-Tyrosine (Gly-Tyr) and an NAD

analog using CAT—Example l and CAT+dimethyla

non-destructively radiolabelling biomolecules by halo

genation, comprising

ing a solution a salt of a radiolabelled halogen.

Also provided for is a method of non-destructively
65

radiolabelling a biomolecule substrate by halogenation,
comprising the steps of:
(a) mixing dry chloramine-T powder or chloramine
T bonded to polymer beads, with a solution of a second
ary amine in molar excess over said chloramine-T pow

5,424,402
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can be used to produce N-Cl-PIP in situ immediately
prior to use in the radiolabelling method of the inven
tion.
Thus, present invention provides a method of nonde

der or chloramine-T bonded to polymer beads, to form
a mixture,

(b) shaking said mixture until all the chloramine-T

powder has dissolved,
(c) adding a solution of KX* or NaX* to said mixture,
wherein X* is a radioisotope of a halogen,

structively radiolabelling a biomolecule substrate by

(d) shaking said mixture of step (c) for a time suffi

(a) reacting a secondary amine with a chlorinating
agent to produce an N-chloro secondary amine,
(b) reacting said N-chloro secondary amine with a

halogenation, comprising the steps of:

cient to release X* in solution,
(e) adding a solution of said biomolecule substrate to

10 salt of a radiolabelled halogen to produce a radi

said mixture,

(1) shaking the resulting mixture of step (e) until the
color disappears, and

olabelled halogenating agent,

I

(c) reacting a solution of said biomolecule substrate
with said radiolabelled halogenating agent, and
(d) recovering a radiohalogenated biomolecule from
the reaction of step (c).
The radio-halogenated biomolecule may preferably

(g) recovering the radiohalogenated biomolecule.
The radioactive iodide is preferably selected from
1211 or 1351 and radioactive bromide is preferably 77Br.
It is preferred that the chloramine-T is in molar excess
over KX* or NaX*, X* is a radioisotope of a halogen.

be recovered by preparative high pressure liquid chro~
matography. The secondary amine may be selected
from dialkylamines, selected from dimethyl amine, di

DESCRIPTION OF THE INVENTION
The invention provides a method of radiolabelling

ethylamine, diisopropylamine, dibutylamine morpho

bioactive molecules with radioactive iodine or other

line and piperidine (PIP).

radioactive halogens such as bromide. Radioactive io
A cation of the salt of the radiolabelled halogen may
dide or bromide are preferred. Examples of radioactive
be selected from the group consisting of sodium, potas
iodide include 1251 and 1311. An example of radioactive
sium, lithium, rubidium, cesium, magnesium, calcium
25
bromide is 77Br.
and ammonium.
Bioactive molecule substrates which may be radi
The chlorinating agent may be selected from chlora
olabelled according to the method of the invention,
mine-T, chloramine-T bonded to polymer beads, hala
include but are not limited to amino acids, peptides,
zone, N-chlorosuccinimide, tetrachloroglycoluril, so

proteins, drug molecules, antibodies, probes and diag
nostic reagents.

30

The bioactive molecule substrates can be used in any

process which requires a radiolabelled molecule. For
example, such bioactive molecule substrates can be used

in radioimmunoassays, enzyme-immunoassays, and for

dium hypochlorite, hypochlorus acid and elemental
chlorine.
The bioactive molecule substrate may include amino

acids, peptides, proteins, drug molecules, drug metabo
lites, antibodies, probes and diagnostic reagents.
The present invention provides a method for non

radiolabelling compounds to determine their location
and/or distribution in animals, including humans.
Certain N-chloroamines have relatively low chlorine

destructively radiolabelling a biomolecule substrate by

potentials, that is, they are relatively poor chlorinating
and oxidizing agents. For example, N-chloro-piperidine

beads, with a solution of a secondary amine in molar

halogenation, including steps of: (a) mixing dry chlora
mine-T powder or chloramine-T bonded to polymer

(N-Cl-PIP) has a chlorine potential of 0.05, whereas 40 excess over chloramine~T powder, to form a mixture,
CAT has a chlorine potential greater than 1. N-Cl~PIP
is a much weaker oxidizing/chlorinating agent than

(b) shaking the mixture until all the chloramine-T pow

der has dissolved, (c) adding a solution of KX* or NaX*
to the mixture, wherein X* is a radioisotope of a halo
CAT. N-Cl-PIP rapidly and quantitatively releases I;
gen, (d) shaking the mixture of step (c) for a time suf?
from I" in solution. This release is so facile that the
active chlorine in N-Cl-PIP can be titrated iodometri 45 cient to release X* in solution which preferably is about
30 seconds, (e) adding a solution of the biomolecule
cally.
substrate to said mixture, (f) shaking the resulting mix
Thus, N-Cl-PIP could be used to release 1*; from I*—
ture of step (e) until the color disappears, and (g) recov
for radioiodination procedures. Unfortunately, N-Cl
ering the radiohalogenated biomolecule.
PIP is not sufficiently stable either in aqueous solution
In an alternative embodiment, the invention provides
or in its pure state to be packaged and sold commer
a method for non-destructively radiolabelling a biomol
cially.
‘

On the other hand, secondary amines, preferably
dialkyl amines including but not limited to diisopropyl

amine, dibutylamine, dimethylamine, morpholine, me

thylethylamine,

2-(N)-methylamino

heptane,

N

ecule substrate by radioiodination, comprising the steps

Of:

(a) mixing dry chloramine-T powder or chloramine
55 T bonded to polymer beads, with a solution of a second

isobutylamine, ethyl-n-butylamine, methyl-sec-butyla

ary amine to reduce the oxidation potential of chlora

mine, and piperidine (PIP), react rapidly and quantita

mine-T, to form a mixture,

form N-Cl-PIP in solution, as follows:
PIP + CAT = N-Cl-PIP + p-toluenesulfonarnide

seconds,

(b) shaking the mixture until all the chloramine-T
tively with CAT to form N-chloro-secondary amines in
powder has dissolved,
solution. Any secondary amine may be used to practice
(0) adding a solution of KI* or NaI* to the mixture,
the invention, and thus the invention need not be limited 60
(d) shaking the mixture of step (c) for a time suf?cient
to the use of dialkylamines. For example, piperidine
to release 1* in solution which preferably is about 30
(PIP) reacts rapidly and quantitatively with CAT to

(P

TSA).
In a preferred embodiment, when the pH is in the
range of 3 to 10, this reaction is complete inabout 30
seconds or less. Since CAT is stable in the dry state, it

(e) adding a solution of the biomolecule substrate to
65 said mixture,

(f) shaking the resulting mixture of step (e) until the
brown color disappears, and

(g) recovering the radioiodinated biomolecule.

5,424,402
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Dry chloramine-T powder or chloramine-T bonded
to polymer beads may be mixed with the secondary
amine in step (a). It is also preferred that the secondary
amine is piperidine (PIP) buffered at about pH 6.0 in

8

Several iodination experiments were run with various
modi?cations of both the new non-destructive method
as compared to a method using CAT bonded to poly

mer beads. The dipeptide, glycine-tyrosine (Gly-Tyr),
and a nicotinamide adenine dinucleotide (NAD) analog

molar excess over chloramine-T powder.

Advantageously, the invention provides a kit for

were chosen as model substrates. The results show that,

non-destructively radiolabelling biomolecules by halo

under optimum conditions, the method of the present

genation, comprising (a) a vial comprising a solution of
invention resulted in up to 4 times more iodine being
KI* or NaI*, and (b) a vial comprising dry chloramine~
taken up by the substrate compared with methods em
T powder or chloramine-T bonded to polymer beads in 10 ploying CAT bonded to polymer beads. In the case of
molar excess over KI*, (c) a vial comprising a solution
Gly-Tyr, the new method produced signi?cantly less
of a secondary amine in molar excess over chloramine
side reaction product.
T powder, (d) instructions for use.
Details of the methods and the exact compositions of
Thus, the present invention provides for a kit for . the solutions are given at the end of this section. The
radioiodination of biomolecules. The kit preferably 5 results are shown as bar charts of counts per minute
consists of two vials. Vial 1 contains a chlorinating
scraped from the thin layer chromatography (TLC)
agent such as dry CAT powder or the CAT bonded to
plates used to separate the iodinated products from the
polymer beads, and Vial 2 contains a solution of a sec

other reaction products.

ondary amine which is preferably, PIP buffered at pH
6.0. To radioiodinate a substrate, Vial 2 is added to Vial 20
l and shaken until all the CAT particles have dissolved.
KI* is then added and the mixture shaken for about 30
seconds or a time suf?cient to release 12* in solution.

DETAILED DESCRIPTION OF THE
'

DRAWINGS

FIG. 1 shows that when CAT was used alone as the

oxidizing agent (Method I, corresponding to the proce

A solution of the substrate, is then added and the
dure of Example 1), the degree of iodination of the two
mixture shaken until the color, brown color in the case 25 substrates was signi?cantly less than when dimethylam
of iodine, disappears. The radioiodinated product may
ine (DMA) was mixed with the CAT one minute before
be recovered by preparative HPLC in the manner
adding the substrate and iodide (Method II, Example
known in the art.
II). FIG. 1 also shows that the amount of a side reaction
After mixing Vial l and Vial 2, it is preferred to en
product formed during the reaction with Gly-Tyr was
sure that all CAT particles are dissolved before the
signi?cantly reduced in the presence of DMA.
substrate is added.
FIG. 2 shows that incubating either the substrate
The kit should contain a secondary amine, such as
iodide-CAT or the substrate-iodide-CAT-DMA system
PIP, in molar excess over CAT to ensure complete
for longer than 30 seconds results in a lower yield of
decomposition of the CAT before the substrate is
iodinated Gly-Tyr and a greater yield of side reaction

product.

added. CAT should be present in molar excess over KI*
to ensure complete conversion of I*— to I*2.

According to the method of the invention it would
not be necessary to hurry any step of this procedure
since 1*; is relatively stable in solution and any reaction
between residual N-Cl-PIP (or other chlorinated sec 40

ondary amine) and the radioiodinated product would

strate and iodide has no effect on the degree of iodin

ation of Gly-Tyr. These results suggest that CAT trans
fers all its chlorine to DMA in the ?rst few seconds
after the substances are mixed.
FIG. 4 shows that increasing the ratio of DMA to
CAT from 1 to 5 does not influence the degree of iodin

occur very slowly, if at all.
In a preferred embodiment the KI* is included in Vial

2, however, it may also‘ be added separately from a third

vial by the researcher during the procedure.

FIG. 3 shows that preincubation of the CAT-DMA
mixture for l, 2, or 3 minutes prior to adding the sub

ation of Gly-Tyr. This also suggests that DMA/CAT
45 ratios greater than 1 may not be needed to protect sub

Below is a flow chart depicting an example of the

strates from decomposition.
FIG. 5 shows the results of three methods employing
Iodobeads® with Gly-Tyr. Method III, which em

radiohalogenation method of the invention. Radioio
dine is used as an example. The molar quantities indi
cated below are intended to show ratios and are in

ployed Iodobeads ® alone, gave signi?cantly less iodi

cluded for illustration only.

nated product than Methods IV and IVa which em

ployed Iodobeads ®+DMA.
FIG. 6 shows a comparison of Method IIa

TYPICAL FLOW CHART FOR RADIOHALOGENATION
'

METHOD

1. Vial l - CAT (dry powder 2 mmol) + Vial 2 - Aqueous

solution buffered at pH 6.0 containing PIP 3 mmol.

55

2. Mix and shake until ALL CAT PARTICLES are dissolved.
3. Add - KI*

1 mmol

Substrate
4. Mix and stand for about 30 seconds.
VIAL CONTENTS
Vial l - Aqueous solution containing
P-TSA

2 mmol

2 mmol

I*-Substrate (labeled)
Substrate (unlabeled)

1 mmol
1 mmol

Note method numbers in the ?gures correspond to
example numbers set forth below in the examples of the
invention.
60

Treat with Sodium

Thiosulfate
5. Preparative HPLC to recover labeled substrate
6. Results in I*-Substrate (labeled) 1 mmol.

(CAT+DMA
solution)
with
Method
IV
(Iodobeads ®+DMA). The results show that Method
IIa gives approximately four-fold greater iodination
than that given by Method IV.
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EXAMPLES
The examples set forth below correspond to the
methods and their results indicated in the ?gures.

COMPARATIVE EXAMPLE I (CAT Solution Only)
5 ttl of Substrate (Gly-Tyr) Solution OR
5 ul Substrate (NAD) Solution
+5 ul NaI Carrier Solution

5,424,402

9

10

+5 pl NaI Labeled Solution

REMOVE 30 pl aliquot

+10 pl CAT Solution

RUN TLC (see Example I)

STIR 30 seconds

7

ADD 30 pl Sodium Thiosulfate Solution
REMOVE 30 “I aliquot
RUN thin layer chromatography (TLC)
For Glycine-Tyrosine: n-butanolzAcOHJIgO, 4:2:1

INVENTION EXAMPLE Iv (I°‘l°beadS ®+DMA
5
Example) (Glycine-Tyrosine only)
Same procedures as Example III, except:
5 pl DMA Solution

For NAD Analog: n-butanolzAcOHzHgo, 5:2:3

+30 pl 0.5M, pH 7.5 Phosphate Buffer was substi

CUT BANDS from TLC

tuted for 30 pl of buffer solution.

DISPERSE in 10 ml water
TRANSFER 2

l

f l

10
t

t

' t'll t'

P’ O C ear Supema e o Scm l a Ion

vials containing 10 ml Fischer Scintillation II liquid
scintillation cocktail.
COUNT using a Packard Model 3375 Tri-Carb Liquid Scintillation Spectrometer.
15

INVENTION EXAMPLE II (CAT+DMA Solution)

INVENTION EXAMPLE IVa (Iodobeads .®+DMA
with Incubation Example) (Glycine-Tyrosine only)

Same procedures as Example IV, except:
Two (2) Iodobeads ®
+5 pl DMA Solution
+30 pl 0.5M, pH 7.5 Phosphate Buffer were incu
bated for 1 minute at room temperature before

(Glycine-Tyrosine only)

being added to the substrate-iodide mixture.

Same procedures as Example I, except:
10 pl CAT Solution was mixed with 10 p1 dimethyl~ 2o
amine (DMA) Solution and incubated 1 min at room

EXAMPLE SOLUTIONS
Substrate Solution (Gly-Tyr)—l mg/ml Glycine

temperature before being added to the substrate-iodide

Tyrosine in 0.5M., pH 7.5 Phosphate Buffer.

mixture.

Substrate Solution (NAD)—1 mg/ml NAD analog in
0.5M., pH 7.5 Phosphate Buffer.

COMPARATIVE EXAMPLE Ia (CAT only)
25
(Glycme'Tyrosme)
Same procedures as Example I, except: The reaction

NaI Carrier Solution—l.5 mg/ml NaI in 0.5M., pH
7.5 Phosphate Buffer.
NaI Labeled Solution-13,000 cpm/pl of NaI125 in

mixture consisting of substrate-iodide-CAT was incu0.005M., pH 7.5 Phosphate Buffer.
bated 0.5, 3 or 6 minutes before adding the Sodium
CAT Solution—5 mg/ml Chloramine-T in 0.05M.,
Thiosulfate Solution.
30 pH 7.5 Phosphate Buffer.
.

Sodium Thiosulfate Solution—5 mg/ml Na2S2O4 in

INVENTION EXAMPLE IIa (CAT+DMA Solution
0.05M. pH 75 Phosphate Buffer.
with Various Incubation Times) (Glycine-Tyrosine
DMA S0lutiOn_2 mg/ml dimethylamine in 0_5M_
only)
pH 7.5 Phosphate Buffer.
Same proceduresasExample II, except: The reaction 35 The foregoing description of the speci?c embodi
mixture consisting of substrate-iodide-CAT-DMA was
incubated 0.5, 3 or 6 minutes before adding the Sodium

ments will so fully reveal the general nature of the in
vention that others can, by applying current knowl

Thiosulfate Solution.

edge, readily modify and/or adapt for various applica
tions such speci?c embodiments without departing
INVENTjION XAMPLE nb & .110 ICAT+DMA 40 from the generic concept and therefore such adapta
Solutton with Various
Incubation
Times
and
.
.
.

tions are intended to be comprehended within the

DMA/CAT Ratios) (Glycme'Tyrosme only)
Same procedures as Example 11, except:

meaning and range of equivalents of the disclosed em
bodiments. It is to be understood that the phraseology

IIb-The DMA+CAT Mixture was incubated for l,
or terminology employed herein is for the purpose of
2, or 3 minutes before addition to the substrate-iodide 45 description only and not of limitation. It will be obvious

mixture (reaction time=3O sec.).

that certain changes and modi?cations may be practiced

IIc-The ratio of DMA/CAT was either 1 or 5 (incu-

within the scope of the appended claims.

bation time=l min.; reaction time=30 sec.).

We claim:
1. A method of non-destructively radiolabelling a

INVENTION EXAMPLE Hd & He (CAT+dialky1 5O biomolecule substrate by halogenation, comprising the
amine Solution)
steps of:
Same procedures as Example II, except:
(a) reacting a secondary amine with a chlorinating
IId—Dibutylamine+CAT Mixture was incubated
for l, 2, or.3 minutes before addition to the substrateiodide mixture (reaction time=30 sec.).
55
IIe-Diisopropylamine+CAT Mixture was incubated for 1, 2, or 3 minutes before addition to the sub-

strate-iodide mixture (reaction time=30 sec.).

said radiolabelled elemental halogen, wherein said
radiolabelled elemental halogen reacts directly

COMPARATIVE EXAMPLE In (Iodobeads ®

Example) (Glycine'Tyrosine only)
+35p 0.5M, pH,75 Phosphate Buffer
+5 pl NaI Labeled Solution

60

with said biomolecule substrate to produce a radi

ohalogenated biomolecule, and

5 pl Substrate (Gly-Tyr) Solution
+5 pl NaI Carrier Solution

agent to produce an N-chloro secondary amine,
(b) reacting said N-chloro secondary amine with a
radiolabelled halide salt to produce a radiolabelled
elemental halogen,
(c) reacting a solution of a biomolecule substrate with

(d) recovering a radiohalogenated biomolecule from
'

the reaction of step (c).

2. The method of claim 1, wherein said radi
65 ohalogenated biomolecule is recovered by preparative

MIX

high pressure liquid chromatography.

ADD two (2) Iodobeads®
STAND 1 minute

3. The method of claim 1, wherein said secondary
amine is selected from dialkylamines.

11

5,424,402

4. The method of claim 1, wherein said secondary

12

amine is selected from the group consisting of dimethyl

11. The method of claim 9, wherein dry chloramine
T powder is mixed with the said secondary amine in

amine, diethylamine, diisopropylamine, dibutylamine,

step (a).

morpholine and piperidine (PIP).

12. The method of claim 9, wherein chloramine-T
bonded to polymer beads is mixed with said secondary

5. The method of claim 1, wherein the cation of said
radiolabelled halide salt is selected from the group con

amine in step (a).
13. The method of claim 9, wherein said secondary
amine is selected from dialkyl amines.

sisting of sodium, potassium, lithium, rubidium, cesium,
magnesium, calcium and ammonium.
6. The method of claim 1, wherein said chlorinating
agent is selected from the group consisting of chlora
mine-T, chloramine-T bonded to polymer beads, hala
zone, N-chlorosuccinimide, tetrachloroglycoluril, so

14. The method of claim 9, wherein said secondary
amine is selected from the group consisting of diisopro

pylamine, dibutylamine and piperidine (PIP).
15. The method of claim 9, wherein said time suf?
cient to release 12* in solution is about 30 seconds.

16. A kit for non-destructively radiolabelling bi

dium hypochlorite, hypochlorus acid and elemental
15
chlorine.
7. The method of claim 1, wherein the biomolecule
substrate is selected from the group consisting of amino

acids, peptides, proteins, drug molecules, drug metabo
lites, antibodies, probes and diagnostic reagents.

(a) a vial comprising a chlorinating agent,
(b) a vial comprising a solution of a secondary amine,
(c) a vial comprising a solution of a salt of a radi

olabelled halogen, and
20

8. A method of producing a radiolabelled halogenat

ing agent for non-destructively radiolabelling a sub
strate by halogenation, comprising the steps of:
(a) reacting a secondary amine with a chlorinating
agent to produce an N-chloro secondary amine,

omolecules by halogenation, comprising

(d) instructions for use.
17. The kit of claim 16, wherein said secondary amine

is selected from dialkylamines.
18. The kit of claim 16, wherein said secondary amine
is selected from the group consisting of diisopropyl
25

amine, dibutylamine and piperidine (PIP).
19. A method of non-destructively radiolabelling a

and

biomolecule substrate by halogenation, comprising the

(b) reacting said N-chloro secondary amine with the

steps of:

salt of a radiolabelled halogen to produce a radi

(a) mixing dry chloramine-T powder or chloramine

olabelled halogenating agent.

T bonded to polymer beads, with a solution of a
secondary amine in molar excess over said chlora
mine-T powder or chloramine-T bonded to poly
mer beads, to form ‘a mixture,

9. A method of non-destructively radiolabelling a

biomolecule substrate by radioiodination, comprising
the steps of:

(a) mixing dry chloramine-T powder or chloramine

(b) shaking said mixture until all the chloramine-T

T bonded to polymer beads, with a solution of a

powder or chloramine-T bonded to polymer beads

secondary amine to reduce the oxidation potential

has dissolved,
(c) adding a solution of KX* or NaX* to said mixture
of step (b), wherein X* is a radioisotope of a halo

of chloramine-T, to form a mixture,

(b) shaking said mixture until all the chloramine-T
powder of chloramine-T bonded to polymer beads
has dissolved,

gen:

(d) shaking said mixture of step (c) for ‘a time suffi
cient to release X* in solution,

(0) adding a solution of KI* or NaI* to said mixture of

(e) adding a solution of a biomolecule substrate to

step (b), wherein 1* represents a radioisotope of

iodine,
(d) shaking said mixture of step (c) for a time suffi
cient to release If in solution,

45

(g) recovering the radiohalogenated biomolecule.
20. The method of claim 19, wherein X* is selected
from the group consisting of radioactive iodide or bro
mide.
21. The method of claim 20, wherein said radioactive

(e) adding a solution of a biomolecule substrate to

said mixture of step (d),
(f) shaking the resulting mixture of step (e) until thev
brown color disappears, and
(g) recovering the radioiodinated biomolecule.
10. The method of claim 9, wherein said secondary
amine is piperidine (PIP) buffered at about pH 6.0 in
molar excess over chloramine-T powder.

said mixture of step (d),
(f) shaking the resulting mixture of step (e) until the
color disappears, and

iodide is selected from the group consisting of 121I, 1351
and said radioactive bromide is 77Br.
22. The method of claim 20, wherein X* is radioac
tive iodide.
55
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